The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

Inclusion Criteria: * 18-75 years； * Histological or cytological confirmed stage Ⅲ and Ⅳa thymoma; * PET/CT or CT/MRI with at least one objectively measurable or evaluable lesion； * Life expectancy \>12months； * ECOG PS 0-1； --Patients with thymoma metastasis； * No found the other malignant tumors (expect has been controlled Carcinoma in situ of the cervix and Basal Cell Carcinoma）； * Informed consent was signed before the study began； * Normal Bone marrow hematopoiesis and renal function，Blood routine: absolute neutrophil count≥1,500/uL，Hb\>8.0g/dL，PLT\>80×10\*9/L，AST≤ 1.5 times the upper limit of normal，TBIL ≤1.5 times the upper limit of normal，calculated creatinine clearance ≤110µmol/L，blood urea nitrogen≤7.1mmol/L； * Cardiac function: LVEF≥55%； * Patients who have not active bleeding or coagulopathy before enrollment； Exclusion Criteria: * -Patients who have been found thymoma metastasis； * Patients with uncontrolled lung disease, Serious infection,active peptic ulcers, coagulation diaorders, Uncontrolled severe diabetes, connective tissue diseases or Bone marrow suppression and Induction therapy for intolerance； * Peripheral neuropathy ≥ Grade 2 (NCI-CTCAE version 5.0 )； * Significant organ dysfunction: such as respiratory failure, NYHA classification Class III or IV, chronic congestive heart failure, decompensation Hepatic or renal insufficiency, high blood pressure（SBP\> 180 mmHg or DBP\> 100mmHg）； * Pregnant and lactating women； * patients without undergo preoperative puncture biopsy or induction therapy； * Patients with active uncontrollable neurological, mental disease or mental disorder, poor compliance, unable to cooperate and describe the treatment response； * Patients who have received any other investigational drug treatment or participated in any other clinical trials within 30 days prior to enrollment in this study； * Known HIV infection or active infection with HBV, HCV. Patients who are infected with HBV but not active hepatitis at the same time are not excluded； * Patients with uncontrollable Stable myasthenia gravis or uncontrollable Serious autoimmune disease such as fulminant DIC； * Patients who are known to be allergic or intolerant to chemotherapy drugs； * severe-trauma； * Patients who have received any other investigational drug treatment or participated in any other clinical trials within 30 days prior to enrollment in this study；